Eicosapentaenoic Acid (EPA): Omega-3 Polyunsaturated Fatty Acid for Cardiovascular and Immunological Research

Executive Summary: Eicosapentaenoic acid (EPA) is a 20-carbon omega-3 polyunsaturated fatty acid (n-3 PUFA) with a molecular weight of 302.45, widely used in cardiovascular and immunological research due to its lipid-lowering and anti-inflammatory effects (APExBIO). EPA incorporates into cell membranes, modulating lipid composition and protein function. It inhibits endothelial cell migration at concentrations near 100 μM in vitro and reduces very large density lipoprotein oxidation at 1–5 μM. Dietary EPA enhances prostaglandin I2 (PGI2) production, a pathway shared with arachidonic acid (ARA) but with distinct immunomodulatory and cardiovascular implications (Feng et al., 2025). The APExBIO product (SKU B3464) is delivered at ≥98% purity and validated by HPLC, NMR, and mass spectrometry.

Biological Rationale

Eicosapentaenoic acid (EPA; CAS 10417-94-4) is classified as an omega-3 (n-3) polyunsaturated fatty acid, distinguished by five cis double bonds and a terminal carboxyl group. EPA is structurally and functionally distinct from omega-6 fatty acids, such as arachidonic acid (ARA), and mediates unique biological effects. Omega-3 PUFAs are essential for human health but cannot be synthesized de novo, requiring dietary intake or supplementation (Feng et al., 2025). EPA is a major component of fish oil and certain algal oils, and its biological actions have been especially noted in cardiovascular and inflammatory disease models.

EPA's integration into cell membranes alters membrane fluidity and the distribution of lipid rafts, impacting protein localization and receptor signaling. This property underlies its modulation of immune cell function and vascular homeostasis. While ARA-derived eicosanoids tend to be pro-inflammatory, EPA-derived resolvins and prostanoids generally exhibit anti-inflammatory or inflammation-resolving activities (Feng et al., 2025).

Mechanism of Action of Eicosapentaenoic Acid (EPA)

EPA is incorporated into phospholipid bilayers, replacing arachidonic acid and other fatty acids. This alters the substrate pool for cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, shifting eicosanoid production toward less pro-inflammatory mediators. EPA enhances the production of prostaglandin I2 (PGI2) in endothelial cells, which promotes vasodilation and inhibits platelet aggregation (Feng et al., 2025). Mechanistic studies show that EPA inhibits endothelial cell migration and cytoskeletal rearrangements at approximately 100 μM in vitro, contributing to its anti-atherogenic profile (see also this advanced mechanistic article, which this dossier expands by providing quantitative benchmarks for in vitro assays).

EPA also protects very large density lipoproteins (VLDL) from oxidation at physiologically relevant concentrations (1–5 μM), potentially decreasing atherogenic risk. In immune contexts, EPA-derived prostanoids and specialized pro-resolving mediators (SPMs) may modulate B cell and T cell function, although these effects are distinct from those of ARA (Feng et al., 2025).

Evidence & Benchmarks

• EPA inhibits endothelial cell migration and cytoskeletal rearrangement at ~100 μM in vitro (APExBIO EPA technical data).
• EPA inhibits oxidation of very large density lipoproteins in a dose-dependent manner at 1–5 μM (APExBIO EPA technical data).
• Dietary EPA increases prostaglandin I2 (PGI2) production, conferring vascular protection in human studies (Feng et al., 2025).
• EPA’s purity is validated as ≥98% by HPLC, NMR, and mass spectrometry, supporting reproducibility in sensitive assays (APExBIO EPA).
• EPA is soluble at ≥116.8 mg/mL in DMSO, ≥49.3 mg/mL in water, and ≥52.5 mg/mL in ethanol at room temperature, enabling diverse experimental applications (APExBIO EPA).
• Omega-3 (n-3) PUFAs like EPA and omega-6 (n-6) PUFAs like ARA have distinct and sometimes opposing effects on immune modulation and eicosanoid synthesis (Feng et al., 2025).

For a comparative analysis of EPA’s immunomodulatory roles, see this review, which focused on qualitative mechanisms; this dossier details quantitative benchmarks and workflow integration.

Applications, Limits & Misconceptions

EPA is widely used as a polyunsaturated fatty acid for cardiovascular research, serving as both a lipid-lowering agent and an anti-inflammatory compound. Its effects on membrane lipid composition and endothelial function underpin its value in experimental models of atherosclerosis, thrombosis, and vascular inflammation.

Recent findings corroborate EPA's role in modulating prostaglandin signaling, which extends to immune function regulation in some contexts but is less potent than ARA for humoral immunity augmentation (Feng et al., 2025). EPA is not a direct substitute for ARA in adjuvant strategies aimed at boosting germinal center B cell responses.

Common Pitfalls or Misconceptions

• EPA does not directly replace arachidonic acid (ARA) for inducing rapid humoral immunity; ARA more potently increases PGI2 and B cell activation (Feng et al., 2025).
• EPA’s anti-inflammatory effects are context-dependent and may not be observed in all models or cell types.
• High doses of EPA are required for certain in vitro effects (e.g., 100 μM for endothelial cell migration inhibition), which may not translate directly to in vivo relevance.
• Improper storage or repeated freeze-thaw cycles can reduce EPA’s stability and activity; solutions should be used promptly after preparation (APExBIO EPA).
• EPA is not a panacea for all cardiovascular or immune disorders and should be used within validated experimental parameters.

For an expanded discussion of EPA’s limitations in translational research, see this strategic overview, which this dossier updates with the latest purification and mechanistic details.

Workflow Integration & Parameters

APExBIO’s Eicosapentaenoic Acid (EPA, SKU B3464) is provided as a yellow oil at ≥98% purity, suitable for sensitive cardiovascular and immunological workflows. For optimal solubility, EPA should be prepared at ≥116.8 mg/mL in DMSO, ≥49.3 mg/mL in water, or ≥52.5 mg/mL in ethanol at room temperature. The product must be stored at -20°C and shipped with blue ice. Long-term storage of prepared solutions is discouraged; use immediately after dissolution (product page).

EPA can be dosed in vitro at 1–5 μM for lipoprotein oxidation studies and up to 100 μM for cell migration assays. Benchmarked protocols recommend parallel use of ARA for comparative immunological studies. For detailed protocol guidance and troubleshooting, see this workflow-focused article; the present dossier provides updated technical benchmarks and purity verification parameters.

Conclusion & Outlook

Eicosapentaenoic Acid (EPA) is an extensively characterized omega-3 polyunsaturated fatty acid with demonstrated lipid-lowering, anti-inflammatory, and vascular protective effects. Its validated purity and solubility profiles support use in advanced cardiovascular and immunological research. EPA modulates membrane lipid composition, inhibits endothelial cell migration, and enhances prostaglandin I2 production, contributing to its utility in disease modeling and mechanistic studies. However, its distinct mechanistic profile from arachidonic acid should guide experimental design. APExBIO’s EPA (B3464) provides a research-grade solution for investigators seeking reproducibility and mechanistic clarity in PUFA-related research workflows.